36 results about "Vaccine Potency" patented technology

The invention discloses application of a broad-spectrum influenza virus polypeptide vaccine in preparation of a medicine for preventing influenza virus infection and controlling influenza virus reinfection, and belongs to the technical field of biological medicine. The vaccine is designed on the basis of artificially synthesized polypeptide, a polypeptide sequence which is highly conservative and has immunocompetence is screened and optimized aiming at various subtype influenza virus proteins, a broad-spectrum polypeptide vaccine P125-H is constructed, and an Ii-Key technology and an MF59 adjuvant are applied to enhance immune response. The vaccine can effectively induce immune protection against H1N1 and H7N9 influenza A viruses, significantly reduce the virus load, reduce pathological injury to the lung and improve the survival rate. The P125-H vaccine is composed of three optimized polypeptides, has a cross protection effect on various influenza virus subtypes, has the potential of being developed into a broad-spectrum influenza vaccine, and provides a new technical scheme for coping with influenza virus variation and improving vaccine efficacy.

Disclosed is a combination vaccine for prevention of influenza and novel coronavirus infections. The combination vaccine for vaccination against influenza and novel corona viruses was obtained by inactivating all influenza virus particles and all novel coronavirus particles respectively, thereby inducing the antibodies to each virus without affecting each vaccine effect, so that the defensive effects were obtained against the attacks of each virus. In addition, the combination vaccine with this combination exhibited favorable neutralizing antibody induction and defensive effects to the attacks of these viruses even without addition of an adjuvant.

The present invention is a multivalent immunogenic composition for immunizing an animal against filariasis. In some embodiments, the antigens of the multivalent immunogenic composition are protein-based, DNA-based, or a combination thereof. This invention also provides a method and kit for detecting a filarial nematode and determining vaccine efficacy.

An effective treatment method for a broad variety of diseases in both animals and humans is disclosed. The method includes combining one or more vaccines with a treatment compound to enhance vaccine efficacy. The disclosed treatment compound does not act directly on the pathogen, and thus the organisms cannot readily develop resistance to the treatment. When a compound such as, but not limited to, the disclosed compound is used in conjunction with one or more vaccines, a synergistic effect is realized. The suggested compound is derived from a lipopolysaccharide (LPS) of gram negative bacteria. The treatment compound is combined with one or more appropriate vaccines and is administered early in the life of an animal to achieve a synergistic effect compared with the use of the treatment compound or the vaccine alone.

Devices and methods are described for utilizing occlusive dressings in combination with topical medicaments to enhance the efficacy of vaccines. The occlusive dressing delivers a defined dose of a topical medicament that enhances the immune system responsiveness of the vaccine to the vaccination site and provides a barrier that maintains the topical medicament layer on the skin for a desired period of time while also providing a port through which the immunization composition can be administered. In some embodiments, the occlusive dressing comprises a wound dressing used to cover the injection site after vaccination.

The invention provides a construction method and application of a chicken fallopian tube embolism model, and belongs to the technical field of animal infection models. The invention provides a construction method of a chicken fallopian tube embolism model based on multi-pathogen infection. The mycoplasma synoviae, the infectious bronchitis virus and the riemerella anatipestifer are utilized to infect the chicken, and the clinical typical salpingemphasis pathological process including cheese-like substance accumulation in a salpingemphasis cavity, serious abdominal air sacculitis complications and related tissue inflammation changes can be accurately reproduced. The model constructed by the invention is high in morbidity, and is suitable for epidemic disease pathogenesis research, drug screening and vaccine potency test. Compared with an existing single pathogen infection model, the model is closer to a clinical reality multi-pathogen cooperative infection scene, and the blank of a standardized multi-pathogen mixed infection induced fallopian tube embolism animal model is filled up.

This invention relates to the field of biomedical technology, specifically to a stably expressed porcine pseudorabies virus gD recombinant protein, a vaccine composition, its preparation method, and its applications. The invention provides a stably expressed porcine pseudorabies virus gD recombinant protein, the amino acid sequence of which is shown in SEQ ID NO:7. The porcine pseudorabies virus gD recombinant protein is stably expressed in monoclonal cells, exhibiting stable expression levels after 48 consecutive passages. This lays a solid foundation for its subsequent applications in the preparation of stable porcine pseudorabies subunit vaccine compositions or in porcine pseudorabies virus vaccine efficacy testing formulations.

Provided herein are engineered T-celi receptors (TCRs) having nanomoiar affinity for the immuno-dominant pp65 peptide residing between residues 495-503 (NLV) in complex with HLA-A2*02:01. The TCRs may be membrane-hound TCRs, soluble TCRs, chimeric TCRs, or chimeric antigen receptors. Also provided are methods of using the engineered TCRs to treat diseases, monitor disease progression, monitor vaccine efficacy, and detecting NLV / A2 presentation on the surface of cells.

The invention provides a quantitative kit for a porcine epidemic diarrhea virus PEDV S protein. The quantitative detection of the PEDV S protein is realized by adopting an ELISA (Enzyme-Linked Immunosorbent Assay) method. The kit comprises a coated elisa plate, an HRP (horse radish peroxidase) labeled monoclonal antibody PEDV-mAb-002, a recombinant PEDV S protein standard substance, a substrate developing solution, a reaction stopping solution, a washing solution and a sample diluent auxiliary reagent. The kit is compared with a standard curve to accurately measure the content of PEDV S protein in a sample. The kit has high sensitivity and high specificity, can accurately detect PEDV S protein at low concentration, has no cross reaction, and ensures the application effect of the kit in actual samples. In performance verification, the kit shows good specificity, sensitivity, precision and correctness, and can meet rapid detection requirements. The kit is simple and convenient to operate, rapid in detection and accurate in result, is suitable for detecting the potency of the PEDV vaccine of the porcine epidemic diarrhea virus, and has relatively high application value and popularization prospect.

The present invention in certain embodiments provides a method of inhibiting PD-1 in a cell by administering a CD200 activation receptor ligand (CD200AR-L) to the cell. The present invention in certain embodiments provides a method of enhancing efficacy of a tumor lysate vaccine in a mammal comprising administering a CD200 activation receptor ligand (CD200AR-L) to the mammal prior to the administration of the tumor lysate vaccine.

The present invention discloses a strain of Lactobacillus mucosus from guinea pigs JL20 and its application, belonging to the field of biomedicine. Lactobacillus mucosus from guinea pigs JL20 was deposited in the General Microbiology Center of the China National Committee for the Collection of Microorganisms on July 19, 2023, with the deposit number CGMCC No. 27949. Lactobacillus mucosus from guinea pigs JL20 can be used as an adjuvant in leptospira vaccines, and has the effects of enhancing vaccine potency, improving antibody quality, and enhancing the reactivity of antigen-presenting cells. It is also convenient to administer, significantly reduces the vaccine dosage, reduces production costs, is safe and has no side effects, and reduces the production of inflammatory side effects caused by vaccine immunization, and has very important application value.

The invention relates to antibodies, or antigen-binding fragments thereof, that specifically binds to killer cell lectin-like receptor G1 (KLRG1). Such antibodies, or antigen-binding fragments thereof, are useful for various therapeutic or diagnostic purposes including treatment of cancers and to increase the effectiveness of vaccines.

Methods and systems for the multiple detection and / or measurement of biomarkers in a sample are provided herein. These methods and systems can be used for rapid disease detection and / or monitoring, monitoring of vaccine efficacy and immune response, monitoring of therapeutic agents, and / or monitoring of the safety and efficacy of treatments.

The invention provides a bivalent vaccine which comprises a rabbit hemorrhagic syndrome virus antigen, a rabbit hepatitis E virus antigen and a microbial freeze-dried slow-release agent, and provides a preparation method which comprises the following steps: culturing the rabbit hepatitis E virus by using passage cells, obtaining the rabbit hepatitis E virus antigen, inoculating the rabbit hemorrhagic syndrome virus, and carrying out freeze-drying on the rabbit hemorrhagic syndrome virus. A rabbit hemorrhagic syndrome virus antigen is obtained, the rabbit hemorrhagic syndrome virus antigen and a rabbit hepatitis E virus antigen are mixed in proportion, a freeze-drying protective agent is supplemented, and the bivalent vaccine is obtained. The invention further provides an application experiment result of the compound, and the compound is used for preventing or treating rabbit hemorrhagic syndrome and rabbit hepatitis E. According to the invention, the two antigens are proportioned properly, so that the prepared vaccine at least achieves the efficacy of preventing and controlling immune epidemic diseases. The bivalent vaccine provided by the invention can prevent two diseases by one injection, reduce immune stimulation, continuously enhance the immune effect of a body, promote the body to generate better immune response, reduce the immune cost, simplify the immune procedure, and is more economical and reliable.

The application belongs to the technical field of biotechnology and relates to the field of veterinary diagnosis, and particularly discloses a liquid-phase blocking ELISA kit for porcine Senecavirus neutralizing antibody, which contains porcine Senecavirus single-domain antibody and matched detection reagents, and the porcine Senecavirus single-domain antibody can also be an antigen-binding fragment of the single-domain antibody, the single-domain antibody is selected from one or more groups in 52 groups, the heavy chain variable region of each group of single-domain antibodies or antigen-binding fragments contains CDR-1, CDR-2 and CDR-3, the amino acid sequences of the heavy chain variable region CDR-1 (VH-CDR-1) of the 52 groups of single-domain antibodies or antigen-binding fragments are respectively shown in SEQ ID NO. 1-SEQ ID NO. 52, the amino acid sequences of the heavy chain variable region CDR-2 (VH-CDR-2) are respectively shown in SEQ ID NO. 53-SEQ ID NO. 104, and the amino acid sequences of the heavy chain variable region CDR-3 (VH-CDR-3) are respectively shown in SEQ ID NO. 105-SEQ ID NO. 156. The kit can quickly detect the SVA neutralizing antibody level in serum, has high sensitivity, good specificity and stable results, and can be better applied to SVA vaccine efficacy evaluation.

The present invention provides an organelle-targeted molecular in situ assembly chimera and its application, belonging to the field of molecular technology. The chimera of the present invention comprises, from N-terminus to C-terminus, an organelle-residence structural unit, an assembly structural unit, a tracer structural unit, and a monomeric streptavidin structural unit, each of which is connected by a linker. The chimera constructed by the present invention assembles biological functional molecules in situ in the organelle region and is applied to various vaccine antigen models. It can significantly enhance antigen-specific immune responses in various vaccine antigen models, improve vaccine efficacy, and enhance the immune protection generated by the vaccine.

This invention belongs to the field of biotechnology, specifically relating to a hybridoma cell line secreting monoclonal antibodies against Clostridium perfringens ETX and its applications. Based on natural toxins, this invention establishes an indirect ELISA detection method using a non-toxic ETX single-amino acid site protein mutant. A series of hybridoma cell lines secreting monoclonal antibodies against Clostridium perfringens ETX were screened. These hybridoma cell lines can stably and efficiently secrete both neutralizing monoclonal antibodies and non-neutralizing monoclonal antibodies, and can be mass-produced on a large scale. This invention is the first to establish an antigen ELISA detection method for Clostridium perfringens ETX using monoclonal antibodies. This method features simple sample handling, low cost, rapid reaction, and high specificity. It can also provide a reference for the diagnosis of Clostridium perfringens infection and lay the foundation for research on alternative methods for testing the efficacy of related vaccines.

The invention discloses a method for rapidly quantifying Seneca virus inactivated antigen protein. The method comprises the following steps: establishing a specific purification technology to obtain a Seneca antigen standard substance, and establishing a linear relation equation between the Seneca antigen content and the chromatographic peak area; meanwhile, a pretreatment method for samples which are not suitable for direct sample loading detection in the Seneca inactivated vaccine production process is established, so that the samples which can be used for detection are obtained; further, in order to eliminate the influence of the target protein loss on the detection result in the sample treatment process, determining the sample recovery rate R in different treatment processes through a labeling recovery test; and finally, through a linear equation and the recovery rate R, calculating to obtain the antigen content of the sample at each stage in the Seneca inactivated vaccine production process. The method is used for directly detecting the content of the Seneca inactivated antigen protein, has the advantages of simple detection operation process and high detection result repeatability, is suitable for each stage of the Seneca inactivated vaccine production process, and can effectively control the Seneca inactivated vaccine production process and the vaccine efficacy.

Aspects of the present disclosure relate to functionalized polymers and methods of use thereof. Certain aspects are directed to polymers comprising adjuvants for use in stimulating an immune response. In some cases, provided are polymers comprising inflammasome activators, in some cases also comprising a TLR agonist, which may be formulated in a pharmaceutical composition. Also disclosed are methods for improving vaccine efficacy and immunotherapy efficacy. Certain aspects relate to compositions and methods for stimulation of CD4+ and / or CD8+ T cell responses in a subject.

This invention discloses a vaccine potency prediction method based on a self-trained model, relating to the field of medical technology. The method constructs a prediction model by collecting spatiotemporal data such as time and temperature during the storage and distribution of vaccines, and continuously trains and optimizes the model parameters using historical data. The system includes data collection, cleaning, model training, and prediction display. This invention achieves rapid, non-destructive, and automated prediction of vaccine potency, improving the efficiency and safety of vaccine lifecycle management.

The inventors found that the overexpression of innate immune response and T cell exhaustion pathways is much more pronounced in pigs than in cattle, making pigs less likely than cattle to mount adaptive immune responses and humoral immune responses. This paper presents an innovative strategy to improve the abnormal immune responses in pigs by simultaneously inducing effective cellular and humoral immune responses and applying T cell agonists as new vaccine adjuvants. This result can provide important clues for understanding the differences in immune responses between cattle and pigs, while presenting a method for maximizing immune responses and vaccine efficacy, which are less expressed in pigs than in cattle.

A nucleic acid vaccine composition comprising one or more of a plasmid-based nucleic acid vaccine and immunotherapy, as well as a lipid formulation, is provided. In addition, the present invention provides a method of enhancing the potency of plasmid-based DNA vaccines and immunotherapies, by formulating a vaccine and / or immunotherapy in a lipid formulation, which is stable when refrigerated or stored frozen, is then delivered to a vaccinee by either needle / syringe, jet injection, or microneedles. The lipid formulation of the present invention comprises one or more lipid excipients selected from 1,2-Distearoyl-sn-glycero-3-phosphocholine, Cholest-5-en-3β-ol, 1,2-Dimyristoyl-rac-glycero-3-methylpolyoxyethlene, and or more symmetric ionizable cationic lipids. The present invention increases vaccine potency dramatically. It was unexpectedly discovered that the level of immunogen, or immune response molecules, produced in vivo is increased (versus administering merely the vaccine or immunotherapy) and, in the case of a vaccine immunogen, the immune response is enhanced.

The invention derives from the discovery that the immunogenicity of piscine orthoreovirus (PRV) can be significantly increased by inactivating the virus in a way different from the prior art: by incubation with an aziridine the vaccine potency against challenge infection by cohabitation is much improved over prior art approaches. This allowed the development of an effective inactivated vaccine against infection and disease caused by PRV.

According to the invention, a Chinese forest encephalitis virus inactivated vaccine is adopted to produce a strain'senzheng 'strain gene sequence, a structural protein preM-E gene sequence of the strain is amplified, an HIV-1 lentivirus packaging system is utilized, preM-E is used as a pseudovirus particle envelope protein, green fluorescent protein (EGFP) or luciferase reporter gene (Luciferae) is used as a detection indication signal to prepare the pseudovirus, and a BHK21 cell is used as a target cell; the pseudovirus-BHK21 cell system is used for replacing live virus operation experiments such as vaccine potency evaluation, neutralizing antibody detection (animal method or plaque reduction neutralization test) and the like, the biosafety operation environment is degraded from BSL-3 to BSL-2 by using pseudoviruses, the detection period is shortened, and animal experiments are reduced.

The invention relates to antibodies, or antigen-binding fragments thereof, that specifically binds to killer cell lectin-like receptor G1 (KLRG1). Such antibodies, or antigen-binding fragments thereof, are useful for various therapeutic or diagnostic purposes including treatment of cancers and to increase the effectiveness of vaccines.

The invention discloses a method for preparing a foot-and-mouth disease subunit recombinant protein vaccine and evaluating immune efficacy of the foot-and-mouth disease subunit recombinant protein vaccine. By optimizing the prokaryotic expression process of the O-type FMDV VP1 protein, the obtained recombinant VP1 protein is mainly expressed in the form of an inclusion body; an adjuvant compatibility scheme adaptive to the recombinant protein is further designed, so that the immunogenicity of the vaccine is enhanced; meanwhile, a mouse-based immune efficacy evaluation method is established, and low-cost and short-period vaccine efficacy evaluation is realized by detecting the immunogenicity of the VP1 protein. The method effectively solves the problems that the prokaryotic expression VP1 subunit vaccine is insufficient in immune efficacy and high in evaluation cost, and provides efficient and practical technical support for research, development and industrialization of foot-and-mouth disease subunit recombinant protein vaccines.

Compositions for determining the efficacy and / or potency of a vaccine preparation are described herein. Splenocytes from immunized animals are isolated and can be frozen. Upon thawing such cells are activated by exposure to a series of dilutions of a vaccine preparation being tested and a series of dilutions of a reference vaccine with known characteristics. Cells secreting immunogen-specific antibody and cells secreting nonspecific antibody are enumerated, as is the amount of immunogen-specific and nonspecific antibody produced. Comparison between the results from the vaccine preparations provides a measure of relative vaccine efficacy and / or potency.

Provided are a vaccine composition for Varicella Zoster virus (VZV) including a glycoprotein E (gE) antigen of VZV and monophosphoryl lipid A (MLA), and a method of using the same. The vaccine composition according to an aspect of the invention may significantly improve a production yield by including the gE antigen having an optimized signal peptide sequence, may enhance immunogenicity by including MLA, and may further enhance the immunogenicity enhanced by MLA by further adding saponin such as QS-21, and may be prepared in a form of CoPoP liposomes so that vaccine antigens may be presented on the surface of the liposomes for better absorption by antigen-presenting cells, and vaccine efficacy may be maximized by inclusion of the vaccine antigens and immune adjuvants in a formulation. Therefore, the vaccine composition may be useful as an alternative to current vaccines in the art for prevention or treatment of VZV infection.

The invention discloses a preparation method and an efficacy evaluation method of a swine mycoplasmal pneumonia inactivated vaccine, and belongs to the technical field of veterinary biological products. The preparation method comprises the following steps: carrying out subculture and fermentation culture on a swine mycoplasmal pneumonia inactivated vaccine strain to obtain a high-density fermentation bacterial liquid, purifying, inactivating, quantifying, and mixing with an adjuvant to prepare the swine mycoplasmal pneumonia inactivated vaccine. The swine mycoplasmal pneumonia inactivated vaccine prepared by the invention is stable among batches, high in antigen content and safe to use. The invention also establishes a method for evaluating the efficacy of the swine mycoplasmal pneumonia inactivated vaccine, the swine mycoplasmal pneumonia inactivated vaccine is evaluated by using the method, and the vaccine is found to have a good challenge protection effect.

Methods are provided for eliciting heterologous immunogenicity against heterologous porcine reproductive and respiratory syndrome virus (PRRSV) strains to allow assessment of innate immunity and adaptive immunity. In other aspects are provided methods for determining the efficacy of a vaccine against PRRSV. In still other aspects are provided methods for predicting the efficacy of a vaccine against PRRSV in pigs suspected of having an infection with PRRSV.